Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: The Belgian experience

Blood

Volumn 105, Issue 7, 2005, Pages 2685-2690

  Gulbis, Béatrice ^b   Haberman, David ^b   Dufour, Dominique ^b   Christophe, Catherine ^b   Vermylen, Christiane ^b   Kagambega, Faustin ^b   Corazza, Francis ^b   Devalck, Christine ^b   Dresse, Marie Françoise ^b   Hunninck, Kathleen ^b   Klein, Axel ^b   Le, Phu Quoc ^b   Loop, Michèle ^b   Maes, Philip ^b   Philippet, Pierre ^b   Sariban, Eric ^b   Van Geet, Chris ^b   Ferster, Alina ^a  

^a HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; HEMOGLOBIN F; HYDROXYUREA;

ACUTE CHEST SYNDROME; ADOLESCENT; ADULT; AGE; ANEMIA; APLASTIC ANEMIA; ARTICLE; BELGIUM; BONE NECROSIS; CEREBROVASCULAR DISEASE; CHILDHOOD DISEASE; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; NEUTROPHIL; NUCLEAR MAGNETIC RESONANCE IMAGING; PARVOVIRUS; PRIORITY JOURNAL; SCHOOL CHILD; SICKLE CELL ANEMIA; STROKE; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; VEIN OCCLUSION; VIRUS INFECTION;

EID: 20144386780     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-07-2704     Document Type: Article

References (26)

1. Charache S, Terrin ML, Moore RD, et al. Effect of hydroyurea on the frequency of painful crises in sickle cell anemia: investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332:1317-1322.
2. Ferster A, Tahriri P, Vermylen C, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood. 2001;97:3628-3632.
3. Ware RE, Zimmerman SA, Schultz WH. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood. 1999;94:3022-3026.
4. Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M. Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. Blood. 2003;102: 1529-1530.
5. Halsey C, Roberts IAG. The role of hydroyurea in sickle cell disease. Br J Haematol. 2003;120:177-186.
6. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289:1645-1651.
7. Wang WC, Wynn LW, Rogers ZR, et al. A two-year pilot trial of hydroxyurea in very young children with sickle cell anemia. J Pediatr. 2001;139: 790-796.
8. De Montalembert M, Belloy M, Bernaudin F, et al. Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease: The French Study Group on Cell Disease. J Pediatr Hematol Oncol. 1997;19:313-318.
9. De Montalembert M, Begue P, Bernaudin F, Thuret I, Bachir D, Micheau M. Preliminary report of a toxicity study of hydroxyurea in sickle cell disease: French Study Group on Sickle Cell Disease. Arch Dis Child. 1999;81:437-439.
10. Kinney T, Helms R, Branski E, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS, a phase I/II trial. Blood. 1999;94:1550-1554.
11. Adams R, Mc Kie V, Nichols F, et al. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med. 1992;326:605-610.
12. Adams RJ, McKie VC, Carl EM, et al. Long-term stroke risk in children with sickle cell disease sreened with transcranial Doppler. Ann Neurol. 1997;42:699-704.
13. Zimmerman S, Schultz W, Davis J, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004;103:2039-2045.
14. Castro O, Brambila DJ, Thorington B, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors: The Cooperative Study of Sickle Cell Disease. Blood. 1994;84:643-649.
15. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al, and the Cooperative Study of Sickle Cell Disease. Cerebrovascular accidents in sickle cell disease: rates end risk factors. Blood. 1998;91: 288-294.
16. Pegelow CH, Adams RJ, McKie V, et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr. 1995;126:896-899.
17. Scothorn DJ, Price C, Schwartz D, et al. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr. 2002; 140:348-354.
18. Ware RE, Zimmerman SA, Sylvestre PB, et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr.2004;145:346-352.
19. Sumoza A, De Bisotti R, Sumoza D, Fairbanks V. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA). Am J Hematol. 2002;71:161-165.
20. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339:5-11.
21. Abboud M, Cure J, Granger S, et al. Magnetic resonance angiography in children with sickle cell disease and abnormal transcranial Doppler ultrasonography findings enrolled in the STOP study. Blood. 2004;103:2822-2826.
22. Benkerrou M, Delarche C, Brahimi L, et al. Hydroxyurea corrects the dysregulated L-selectin expression increased H(2)O(2) production of polymorphonuclear neutrophils from patients with sickle cell anemia. Blood. 2002;99:2297-2303.
23. Styles LA, Lubin B, Vichinsky E, et al. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Blood. 1997;89:2554-2559.
24. Ferster A, Sariban E, Meuleman N; Belgian Registry of Sickle Cell Disease patients treated with Hydroxyurea. Malignancies in sickle cell disease patients treated with hydroxyurea. Br J Haematol. 2003;123:368-369.
25. Hanft VN, Fruchtman SR, Pickens CV, Rosse WF, Howard TA, Ware RE. Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood. 2000;95:3589-3593.
26. Hoppe C, Vichinsky E, Quirolo K, Van Warmerdam J, Allen K, Styles L. Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease. J Pediatr Hematol/Oncol. 2000;22:330-334.